The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO 2015 | Results for the follow-up of the RESPONSE study

Name: Results for the follow-up of the RESPONSE study
Uploaded: 2015-06-02T00:00:00.000Z
Duration: 1 min 46 s
Description: Dr Jean-Jacques Kiladjian discusses the results of the follow up to the RESPONSE study of ruxolitinib versus standard therapy for the treatment of patients with polycythemia vera.

Jean-Jacques Kiladjian • 2 Jun 2015

ASCO 2015

Myeloproliferative Neoplasms Ruxolitinib

Dr Jean-Jacques Kiladjian discusses the results of the follow up to the RESPONSE study of ruxolitinib versus standard therapy for the treatment of patients with polycythemia vera.